Diamond-Blackfan anemia 17

disease
On this page

Also known as DBA17

Summary

Diamond-Blackfan anemia 17 (MONDO:0044310) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameDiamond-Blackfan anemia 17
Mondo IDMONDO:0044310
OMIM617409
DOIDDOID:0111880
UMLSC4479428
MedGen1373199
GARD0016228
Is cancer (heuristic)no

Also known as: DBA17 · Diamond-Blackfan anemia 17

Data availability: 2 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › hematologic disorderanemiapure red-cell aplasiaDiamond-Blackfan anemiaDiamond-Blackfan anemia 17

Related subtypes (21): Diamond-Blackfan anemia 1, Diamond-Blackfan anemia 14 with mandibulofacial dysostosis, Diamond-Blackfan anemia 2, Diamond-Blackfan anemia 15 with mandibulofacial dysostosis, Diamond-Blackfan anemia 3, Diamond-Blackfan anemia 4, Diamond-Blackfan anemia 5, Diamond-Blackfan anemia 6, Diamond-Blackfan anemia 7, Diamond-Blackfan anemia 8, Diamond-Blackfan anemia 9, Diamond-Blackfan anemia 10, Diamond-Blackfan anemia 11, Diamond-Blackfan anemia 12, Diamond-Blackfan anemia 13, Diamond-Blackfan anemia 21, Diamond-Blackfan anemia 18, Diamond-Blackfan anemia 19, Diamond-Blackfan anemia 20, Diamond-Blackfan anemia 16, Diamond-Blackfan anemia 22

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 benign, 1 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
417765NM_001030.6(RPS27):c.90del (p.Tyr31fs)LOC126805872Pathogenicno assertion criteria provided
1327974NM_001030.6(RPS27):c.116-45_116-44dupLOC126805872Benigncriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 2 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
RPS27LimitedUnknownDiamond-Blackfan anemia 172

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RPS27Orphanet:124Diamond-Blackfan anemia

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
RPS27HGNC:10416ENSG00000177954P42677Small ribosomal subunit protein eS27gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RPS27Small ribosomal subunit protein eS27Component of the small ribosomal subunit.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
RPS27Other/UnknownnoRibosomal_eS27, Ribosomal_zn-bd, Ribosomal_eS27_Zn-bd_dom_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
ganglionic eminence1
granulocyte1
lymph node1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
RPS27134ubiquitousmarkerganglionic eminence, granulocyte, lymph node

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
RPS273,809

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
RPS27P42677214

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 68. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Eukaryotic Translation Initiation1308.6×0.018RPS27
Cap-dependent Translation Initiation1308.6×0.018RPS27
SARS-CoV-1 modulates host translation machinery1308.6×0.018RPS27
Eukaryotic Translation Elongation1278.5×0.018RPS27
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S1271.9×0.018RPS27
Nonsense-Mediated Decay (NMD)1233.1×0.018RPS27
SARS-CoV-2 modulates host translation machinery1223.9×0.018RPS27
Influenza Viral RNA Transcription and Replication1215.5×0.018RPS27
Formation of the ternary complex, and subsequently, the 43S complex1215.5×0.018RPS27
Amplification of signal from the kinetochores1196.9×0.018RPS27
Selenoamino acid metabolism1196.9×0.018RPS27
Translation initiation complex formation1190.3×0.018RPS27
Ribosomal scanning and start codon recognition1190.3×0.018RPS27
Influenza Infection1175.7×0.018RPS27
SARS-CoV-1-host interactions1175.7×0.018RPS27
Cellular response to starvation1165.5×0.018RPS27
rRNA processing in the nucleus and cytosol1160.8×0.018RPS27
Mitotic Spindle Checkpoint1158.6×0.018RPS27
rRNA processing1146.4×0.018RPS27
SARS-CoV-1 Infection1142.8×0.018RPS27
Peptide chain elongation1126.9×0.018RPS27
Viral mRNA Translation1126.9×0.018RPS27
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA1125.5×0.018RPS27
Signaling by ROBO receptors1124.1×0.018RPS27
Selenocysteine synthesis1120.2×0.018RPS27
Eukaryotic Translation Termination1120.2×0.018RPS27
SARS-CoV-2-host interactions1119.0×0.018RPS27
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)1117.7×0.018RPS27
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA1117.7×0.018RPS27
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal1116.5×0.018RPS27

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
ribosomal small subunit assembly11404.3×0.004RPS27
ribosomal small subunit biogenesis1227.7×0.009RPS27
cytoplasmic translation1185.2×0.009RPS27
rRNA processing1141.6×0.009RPS27
translation1102.8×0.010RPS27

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
RPS27GENTAMICIN SULFATE

Top cohort targets by molecule count

SymbolMoleculesMax phase
RPS2714

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
GENTAMICIN SULFATE4RPS27

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
RPS2797Binding:97

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
GENTAMICIN SULFATE4RPS27

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1RPS27
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.